FDA warns Pensar Medical over unreported wound-therapy injuries and missing device reporting procedures.
What happened
FDA inspected the Houston, TX facility from April 14 to April 28, 2026, and found the company's medical device reporting (MDR) procedure lacked required definitions and recordkeeping, and that a patient infection complaint from May 2024 was never reported as a serious injury. FDA also found the company corrected MicroDoc software for customers without filing a required correction report, and found incomplete risk management, change control, and corrective action records.
What FDA found
The written procedure for reporting device problems did not define what "reasonably suggests" a reportable event, so staff could decide wrongly.
21 CFR 803.17(a)(1)The procedure did not describe how the company would keep records and document its reporting decisions.
21 CFR 803.17(b); 21 CFR 803.18(b)(1)(i)The company did not report a patient's wound-site infection within 30 calendar days, and later filed it as a malfunction instead of a serious injury.
21 CFR 803.50(a)(1); 21 CFR 803.52(f)The company updated MicroDoc software for customers with the wrong version but did not file a correction report with FDA within 10 working days.
21 CFR 806.10Risk management files were incomplete: PocketDoc risk controls were still "In Progress," no WoundPro risk analyses existed, and no interim risk plan was described.
ISO 13485:2016, Clause 7.1Eleven software and firmware changes were approved and closed without records showing they were verified or actually installed, and corrective action records were closed with blank root causes and no effectiveness checks.
ISO 13485:2016, Clauses 7.3.9 and 8.5.2
What FDA wants
FDA asks the company to write within 15 business days describing the specific steps taken to fix all violations and prevent recurrence, with documentation and a timetable for anything still ongoing. The company must also submit corrected data for the misreported MDR and file the missing correction and removal report.
Who should pay attention
- home-care and wound-care providers using these devices
- distributors and buyers of NPWT systems
- companies relying on complaint and MDR procedures for devices
This is a summary. Read the original letter on fda.gov.